|
|
Article: BMY: Plavix Small Worry - Analyst Blog
- Article from:
- Zacks Investment Research - Analyst Blog
- Article date:
- July 25, 2008
- Author:
-
|
Copyright informationCopyright 2008 Zacks Investment Research. (Hide copyright information)
|
BMY: Plavix Small Worry - Analyst Blog
Growth of mega-blockbuster Plavix is helping
Bristol-Myers Squibb Company
(
BMY
) drive EPS growth up near 13% in 2008. Patent expirations loom very large in Bristol's future starting in 2011 when the Plavix patent expires. That being said, the company does have an attractive mid-to-late-stage pipeline, and the company has been dramatically working to reduce costs and shed less profitable and non-core businesses.
We believe the company is an attractive take-over candidate at this level for a larger pharma name such as
Sanofi-Aventis SA
(
SNY
) or
Pfizer Inc.
(
PFE
). EPS growth at rates near the top of big pharma and a very attractive valuation ...
Related newspaper, magazine, and journal articles:
|